Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities

Ara Aboolian, Sofia Urner, Michael Roden, Jay Chandra Jha, Karin Jandeleit-Dahm

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

5 Citations (Scopus)

Abstract

One of the microvascular complications of diabetes is diabetic kidney disease (DKD), often leading to end stage renal disease (ESRD) in which patients require costly dialysis or transplantation. The silent onset and irreversible progression of DKD are characterized by a steady decline of the estimated glomerular filtration rate, with or without concomitant albuminuria. The diabetic milieu allows the complex pathophysiology of DKD to enter a vicious cycle by inducing the synthesis of excessive amounts of reactive oxygen species (ROS) causing oxidative stress, inflammation, and fibrosis. As no cure is available, intensive research is required to develop novel treatments possibilities. This chapter provides an overview of the important pathomechanisms identified in diabetic kidney disease, the currently established therapies, as well as recently developed novel therapeutic strategies in DKD.

Original languageEnglish
Title of host publicationFrom Obesity to Diabetes
EditorsJuergen Eckel, Karine Clément
Place of PublicationCham Switzerland
PublisherSpringer
Pages269-307
Number of pages39
ISBN (Electronic)9783030999957
ISBN (Print)9783030999940
DOIs
Publication statusPublished - 2022

Publication series

NameHandbook of Experimental Pharmacology
PublisherSpringer
Volume274
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Keywords

  • Diabetic kidney disease
  • Diabetic nephropathy
  • Fibrosis
  • Inflammation
  • NADPH oxidase
  • Oxidative stress

Cite this